Navigation Links
ERT Reports First Quarter 2009 Results
Date:4/30/2009

es 25,273 16,817 Site support 7,775 6,260 Total net revenues 33,673 23,786 Costs of revenues: Cost of licenses 200 205 Cost of services 10,514 7,954 Cost of site support 5,268 3,635 Total costs of revenues 15,982 11,794 Gross margin 17,691 11,992 Operating expenses: Selling and marketing 3,323 3,426 General and administrative 4,873 4,077 Research and development 999 1,149 Total operating expenses 9,195 8,652 Operating income 8,496 3,340 Other income, net 427 116 Income before income taxes 8,923 3,456 Income tax provision 3,177 1,386 Net income $5,746 $2,070 Basic net income per share $0.11 $0.04 Diluted net income per share $0.11 $0.04 Shares used to calculate basic net income per share 50,638 50,879 Shares used to calculate diluted net income per share 51,894 51,164


                   eResearchTechnology, Inc. and Subsidiaries
                            Consolidated Balance Sheets
               (in thousands, except share and per share amounts)

                                        December 31,
'/>"/>
SOURCE eResearchTechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. CryoLife Reports Record First Quarter Revenues of $26.7 Million
2. Caliper Life Sciences Reports First Quarter 2009 Results
3. Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets
4. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
5. Vanda Pharmaceuticals Reports First Quarter 2009 Results
6. Telik Reports Preclinical Results at AACR Annual Meeting
7. PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results
8. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
9. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
10. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
11. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 “2014 Deep Research ... Industry” is a professional and in-depth research ... introduces Polyurethane Resin basic information, including its ... and industry overview. This research covers the ... as well as global industry analysis covering ...
(Date:7/31/2014)... see through organs and even the entire body to ... cellular structures has been a long-time dream of biologists. ... 31st in the journal Cell has now ... making opaque organs, bodies, and human tissue biopsies transparent, ... protocols could pave the way for a better understanding ...
(Date:7/31/2014)... 2014 Rogne Bioscience, a privately-held biotechnology company ... , has acquired a licence to anti-inflammatory peptides from ... potent anti-inflammatory activity of the peptides was discovered by ... Oxford,s Sir William Dunn School of Pathology. ... $1.5 million in seed financing, is developing a first-in-class, ...
(Date:7/31/2014)... San Francisco, California (PRWEB) July 31, 2014 ... expert systems that inform therapeutic decision-making in oncology, today ... on August 14, 2014 to discuss the Company's financial ... to provide an update about the business in the ... live audio call beginning on Thursday, August 14, 2014, ...
Breaking Biology Technology:Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4See-through organs and bodies will accelerate biomedical discoveries 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2
... (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ... virus (HCV) infection, today announced that it will release ... 2008 on March 11,2008 at 7:00 a.m. EDT and ... results at 11:30 a.m. EDT on the same day., ...
... (Nasdaq,CM: INSM), a developer of follow-on biologics and biopharmaceuticals, today,reported results for ... and Recent Company Highlights, -- Follow-on Biologics Program ... Factor or G-CSF) ... products to enter clinical trials in 2008; ...
... Vical Incorporated,(Nasdaq: VICL ) today announced ... Officer, will participate in a roundtable discussion,"An Industry ... in,Global Health Product Development," and present an overview ... on Tuesday,March 11, at the Biotechnology Industry Organization ...
Cached Biology Technology:Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 3Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 4Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 5Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 6Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 7Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 8Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 9Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 10Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 11Vical to Present at BIO and BVGH Global Health Partnering Event 2Vical to Present at BIO and BVGH Global Health Partnering Event 3
(Date:8/1/2014)... fossil record about 200,000 years ago, but it was ... advanced tools became widespread. , A new study ... finds that human skulls changed in ways that ... same time that culture was blossoming. , "The modern ... cultural exchange probably came at the same time that ...
(Date:8/1/2014)... Knowing what causes them at the molecular level is ... have created the most detailed map to date of ... blinding diseases, such as age-related macular degeneration. The high-resolution ... which supplies blood and oxygen to the outer retina, ... abundance of proteins in different areas of the choroid, ...
(Date:8/1/2014)... One of the most diverse families in the ocean ... lucinids) -- originated more than 400 million years ago ... like those of its modern members. This Geology ... Hawaii, published online on 25 July 2014, tracks the ... relationships. , At is origin, the Lucinidae family remained ...
Breaking Biology News(10 mins):Society bloomed with gentler personalities and more feminine faces 2A map for eye disease 2Symbiotic survival 2Symbiotic survival 3Symbiotic survival 4Symbiotic survival 5Symbiotic survival 6Symbiotic survival 7Symbiotic survival 8Symbiotic survival 9Symbiotic survival 10Symbiotic survival 11Symbiotic survival 12Symbiotic survival 13Symbiotic survival 14
... A method to detect contaminants in municipal water supplies ... Laboratory researchers whose findings are published on line in ... demonstrates that the technology that uses algae as sentinels ... Miguel Rodriguez Jr. and Elias Greenbaum of the Department ...
... Calif., August 27, 2009 -- Researchers at Burnham ... Southwestern Medical Center and University of Maryland have ... many bacteria can be targeted to kill dangerous ... can inhibit this enzyme and suppress the growth ...
... A new candidate gene for Specific Language Impairment has ... Rice at the University of Kansas, in collaboration with ... Gayn of Neocodex, Seville, Spain. The finding, reported in ... Disorders , was discovered by examining genes previously identified ...
Cached Biology News:ORNL scientists hone technique to safeguard water supplies 2The path to new antibiotics 2Researchers report gene associated with language, speech and reading disorders 2
... LUMIstar OPTIMA is a fully automated ... for the widest possible range of ... Reporter gene assays luciferase, -galactosidase, gene ... esters, dioxetanes..) Luminescent Immunoassays ...
... depleted sera are specifically depleted of a ... the depleted protein, the alternative and classical ... therefore ideal for the detection and quantitation ... have been used to assess complement activation ...
... The latest generation of the ... M.I.T. for the iontophoresis of neural ... (HRP) or tritiated amino acids into ... Stoelting. It may also be used ...
... In situ detection of apoptosis and ... event provides an early indication of the ... typically defined as a collapse in the ... measured by the change in the membrane ...
Biology Products: